Theratechnologies signs distribution and licensing agreement for EGRIFTA™ in Latin America, Africa and the Middle East with sanofi-aventis

On December 6, 2010, Canadian biopharmaceutical company Theratechnologies (TSX:TH) announced that it had signed a distribution and licensing agreement with sanofi-aventis ("Sanofi"), for the commercialization rights to EGRIFTA™ (tesamorelin for injection) in Latin America, Africa and the Middle East for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.

Under the terms of the agreement, Theratechnologies will be responsible to supply EGRIFTA™ to Sanofi. Theratechnologies has kept all future development rights to EGRIFTA™ and will be responsible for conducting research and development for any additional programs. Sanofi will be responsible to conduct all regulatory activities in the aforementioned territories in connection with EGRIFTA™ for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, including seeking the approval of EGRIFTA™ in the different countries. Theratechnologies granted Sanofi an option to commercialize EGRIFTA™ in the aforementioned countries for other uses.

Theratechnologies was advised in the negotiation of this agreement from the London office of Fasken Martineau by Stuart Richards and Antonina Cuffaro.